Eight driver genes, EGFR, ROS1, MET, RET, ALK, ERBB2, KRAS, and BRAF, are recommended by the NCCN guideline to inform the selection of effective targeted therapies for NSCLC patients. The gene discussed is RET; the disease is non-small cell lung carcinoma.